IRON
Disc Medicine, Inc.
NASDAQ · Healthcare · Biotechnology · US
$81.17
−2.02%Oct 21, 2026, 00:52 UTC
Disc Medicine, Inc. announced pricing of an underwritten public offering of 6,000,000 common shares at $75 per share, with expected gross proceeds of $450 million before expenses, excluding any exercise of the underwriters’ option.
Source:Oct 19, 2026, 20:01 UTC
Disc Medicine, Inc. announced the commencement of an underwritten public offering of $350 million of common stock and, for certain investors, pre-funded warrants to purchase common stock.
Source:Oct 19, 2026, 14:09 UTC
Disc Medicine, Inc. shares rose 34.92% to $76.69 during U.S. trading.
Source:Oct 19, 2026, 14:09 UTC
Disc Medicine, Inc. announced that its phase 3 APOLLO trial of bitopertin met all primary and secondary endpoints in adults and adolescents with erythropoietic protoporphyria.
Oct 19, 2026, 12:06 UTC
Disc Medicine, Inc. reported that its rare disease drug succeeded in a late-stage trial.
Source:Oct 19, 2026, 09:30 UTC
Disc Medicine, Inc. shares surged 41%.
Jun 30, 2026, 00:00 UTC
Disc Medicine, Inc. amended its secured credit facility with Hercules Capital, Inc. on June 25, 2026, extending drawdown periods, splitting the $50 million Tranche 1-C Advance into two $25 million tranches, and drawing down $30 million of the Tranche 1-B Advance.
Jun 9, 2026, 12:30 UTC
Disc Medicine completed a Type A meeting with the FDA to discuss the Complete Response Letter for bitopertin in erythropoietic protoporphyria.
Source: